Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference
08 Juni 2023 - 2:00PM
Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”)
(Nasdaq: RANI), a clinical-stage biotherapeutics company focused on
the oral delivery of biologics and drugs, today announced that a
late-breaking abstract “Oral Delivery of a GLP-1 Agonist with High
Bioavailability in Dogs and Humans” has been selected for poster
presentation at the American Diabetes Association’s (ADA)
Scientific Sessions taking place on June 23 - 26, 2023 in San
Diego, CA.
The details of the presentation are as
follows:
Poster Title: Oral Delivery of a GLP-1 Agonist
with High Bioavailability in Dogs and HumansPoster
Identifier: 89-LB Poster Category: 12-D
Clinical Therapeutics – Other Therapeutic AgentsDate &
Time: Saturday June 24, 2023, 11:30am-12:30pm
PTLocation: San Diego Convention
CenterPresenter: April T Vo, MS
Information about ADA 2023 may be accessed at
https://professional.diabetes.org/scientific-sessions.
About Rani Therapeutics
Rani Therapeutics is a clinical stage biotherapeutics company
focused on advancing technologies to enable the development of
orally administered biologics and drugs. Rani has developed the
RaniPill® capsule, which is a novel, proprietary and patented
platform technology, intended to replace subcutaneous injection or
intravenous infusion of biologics and drugs with oral dosing. Rani
has successfully conducted several preclinical and clinical studies
to evaluate safety, tolerability and bioavailability using
RaniPill® capsule technology. For more information,
visit www.ranitherapeutics.com.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
media@ranitherapeutics.com
Rani Therapeutics (NASDAQ:RANI)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Rani Therapeutics (NASDAQ:RANI)
Historical Stock Chart
Von Mai 2023 bis Mai 2024